Phibro Animal Health (NASDAQ:PAHC) Trading Up 5.2% – What’s Next?

Phibro Animal Health Corporation (NASDAQ:PAHC)’s stock price shot up 5.2% during mid-day trading on Friday . The company traded as high as $38.38 and last traded at $38.24. Approximately 21,217 shares were traded during trading, a decline of 93% from the average session volume of 294,857 shares. The stock had previously closed at $36.35.

Analyst Upgrades and Downgrades

Several equities research analysts recently issued reports on PAHC shares. Weiss Ratings cut shares of Phibro Animal Health from a “buy (b-)” rating to a “hold (c+)” rating in a report on Monday, June 15th. Zacks Research downgraded Phibro Animal Health from a “strong-buy” rating to a “hold” rating in a report on Thursday, May 21st. Citigroup decreased their price target on Phibro Animal Health from $62.00 to $44.00 and set a “neutral” rating for the company in a research note on Thursday, May 14th. Finally, Wall Street Zen lowered Phibro Animal Health from a “strong-buy” rating to a “buy” rating in a research note on Saturday, May 9th. One research analyst has rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Phibro Animal Health currently has an average rating of “Hold” and an average price target of $42.50.

Phibro Animal Health Stock Performance

The company has a quick ratio of 1.26, a current ratio of 3.17 and a debt-to-equity ratio of 1.97. The stock has a market cap of $1.54 billion, a PE ratio of 15.58, a P/E/G ratio of 0.51 and a beta of 0.46. The stock has a 50-day moving average of $34.04 and a 200 day moving average of $42.32.

Phibro Animal Health (NASDAQ:PAHC) last issued its earnings results on Wednesday, August 26th. The company reported $0.85 EPS for the quarter, topping the consensus estimate of $0.71 by $0.14. Phibro Animal Health had a net margin of 6.57% and a return on equity of 39.28%. The company had revenue of $396.75 million for the quarter, compared to analyst estimates of $381.18 million. Phibro Animal Health has set its FY 2027 guidance at 3.410-3.590 EPS. Equities analysts predict that Phibro Animal Health Corporation will post 3.33 EPS for the current fiscal year.

Phibro Animal Health Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, September 23rd. Shareholders of record on Wednesday, September 2nd will be given a dividend of $0.12 per share. This represents a $0.48 annualized dividend and a yield of 1.3%. The ex-dividend date of this dividend is Wednesday, September 2nd. Phibro Animal Health’s dividend payout ratio is presently 20.60%.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the stock. 1620 Investment Advisors Inc. lifted its position in shares of Phibro Animal Health by 77.4% in the 4th quarter. 1620 Investment Advisors Inc. now owns 676 shares of the company’s stock worth $25,000 after acquiring an additional 295 shares during the period. Farther Finance Advisors LLC raised its stake in shares of Phibro Animal Health by 113.2% in the fourth quarter. Farther Finance Advisors LLC now owns 727 shares of the company’s stock valued at $27,000 after purchasing an additional 386 shares in the last quarter. KBC Group NV bought a new position in Phibro Animal Health in the first quarter worth $29,000. Rothschild Investment LLC lifted its position in Phibro Animal Health by 2,500.0% in the fourth quarter. Rothschild Investment LLC now owns 1,040 shares of the company’s stock worth $39,000 after purchasing an additional 1,000 shares during the period. Finally, iSAM Funds UK Ltd acquired a new stake in Phibro Animal Health during the third quarter worth $61,000. Institutional investors and hedge funds own 99.34% of the company’s stock.

Phibro Animal Health Company Profile

Phibro Animal Health Corporation (NASDAQ: PAHC) is a diversified global animal health and mineral nutrition company headquartered in Teaneck, New Jersey. The company develops, manufactures and markets a broad range of pharmaceutical, mineral nutrition and performance products designed to support the health and productivity of livestock, companion animals and aquaculture species. Phibro’s portfolio includes vaccines, anti-infective therapies, coccidiostats, disinfectants, premix minerals and specialty feed additives aimed at enhancing growth, immunity and overall animal well-being.

The company operates through three principal business segments: Animal Health, Mineral Nutrition and Performance Products.